PO I NTS • • Neuropa th ic pain is defined as "pain arising as a direct consequence of a lesion or d isease aflecrlng the soma tosensory system".
Recent developments in neuropathic pain mechanisms implications for treatment
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Cha racrerlsrlc symproms include an increased evoked pai n response to noxious (hyperalgesia) and innocuous (allodynia) stim uli, sponta neous pain, shooring electric shock like pain. Sensory deficits can also exist.
• Available treatm ents are no t adequate in m any pati ents due to many factors includ ing the complexity of the pain state, disease progression, intolerable side effects and low analgesic efficacy.
• A number of peri pheral, spinal and supraspinal mechanisms o f hyperexcitab ility underlie neuropathi c pain , these include cha nges in rhe activity and expression of volta ge gated sod ium, calcium and pota ssium channels, as well as T RPVl channels and alterations in rhe activity of neuroimmue pathways.
• NeP patient s often experience depression , anxiety, sleep distu rbances etc. alon gside their pain . These (0mor bldi res stgnificanrly red uce quality of life and as such are key treatment considerations..
• Improved understand ing of NeP mechanisms is encouraging rargering of treatm ent ro the mechan isms thar produce pain ful symptoms as opposed to the etiology o f d isease.
Intr oduct io n Neuropathic pain (Ne P) can arise as a direct consequence of a lesion or dise 'ase affecting the so matosenso ry system. Initiatin g factors are varied and include cancer, metabolic disord ers and viral infections', C linically. sym pto ms include an Increased evoked pain response ro noxious (hyperalgesia) and innocuo us (allody nia] stim uli an d spo nt aneous shoot ing electric shock like pain. Addit ion ally, pain has an affective w mpo nem , and so co-mo rb id ities suc h as fatigue. anxiety and depression can occur. wh ich int eract with the sensory aspe.:ts of the pa in to subst ant ially redu ce q uality ofHfe in Ne P patients and are part of the med ical problem' .
Nel' treatme nt rem ains a large un mer clinical need and this has served as a powerful research st imul us int o the patho physiological mechanis ms that underlie NeP, thu s forming the basis for targeted d rug therapy' ·J. Th is review highlight s som e of the key mechanism s.
Mechan isms of Ne ur o pathic Pain
Mechanisms of Ncr include ecro plc {spontaneo us] nerve act fvfty, peripheral and cent ral sensitlsatio n, phenotypic switching of periphera l nerve fibres and structu ral plasdctry within the central nervous syste m. At the molecular lev el th ese l:hanges can be d riven by changes in functio n and expressio n of multiple channels. rlX~'ptol> and ind uction of new genes, som e ofwhich are derailed below.
Pt'riphrml mechanisms
Following nerve lesio n, damaged and un injured primary afferent neuro nes display ectopic (spo ntaneo us) act ivity that drives Nel ".
Ectopic activity, which serves as a raw pain signal and an ind ucer of cent ral sensinsancn. has been related 10 nerve injury-i nd uced changes in the distribution, accumulanon, clustering and funct io nal activities of voltage-gated sod ium cha nnels (Na) 1.7 ana 1.8, and th e a re-em ergence of th e embryonic Na, 1.3 ch ann el' .
There is co nsiderable evidence link ing the red uced inactivation kinetics ofNa, chan nels to Ne P'. Com pelling evidence for the Na 1.7 subtype in pain signalling comes fro m hum an genetic studies wh ere a gain or loss of functi o n m urario n in {he encodi ng gene, SC N9 A, causes pain in eryt hromelalgia patie nts or a co ngenital absence of pain pc rcepnon res pectively' . Sur prisingly, NcP behaviors develop as normal in Na, 1.3. 1.7 and 1.8 knockout mice' . Despite these cont radicricns, rode nt studies have improved un dema nd ing of Na, channels and their co ntribut ion !O Ner. These have led ro the development of a porent and selective small molecule Nav 1.8 blocker (A-803467)". the d iscovery ofa novel class of benzazeplno ne Nn 1.7 blockers' and a newly synthesized rocalolde congene r, NePI , rhar blocks Nav 1.7 channels. prod ucing significant reversal of allody n!a and am i-hyperalgesia in neuropa thic rars'", reinforcin g rhe case for Na. 1,8 and 1.7 as ana lgesic targets for Ner.
Voltage gated potassium chan nels (K) cha nnels ser resting mem bra ne pote ntials and repolarbe action potentials. thus limiting neu ronal excirabiliry Pathological cha nges in channel activity have been demon strated" and a recent generic srudy foun d rhar the potassium cha nnel alph a sub un u, KeNS1 , involved in neuro nal exdrabtltry is markedly down -regulared in sensory neu rons in neuropathic rats. Importa ntly the KC NSI allele, rs734784 , was stro ngly associated with Ne P in humans's. Target ing K, channels for Nel' treatment has yet to prove successful, however furth er research is warrant ed given the human genetic evide nce !", H yperpolarisanon-acrivated cyclic nucleorid e-gated (H C N) chan nels also generate spontaneo us rhythmic activity an d play an important role in mod ulating neuron al excirabiliry and plasriciry Ne uropurhy resulrs in increased HC N I expression in dorsal root ganglia (DRG ) and sponta neous act ivity in damaged nerves, and antago nism decreased ectopic activity and allodynia " .
Peripheral senshiza rlon of primary afferent neuron s, which may result in reduced thr esholds, spontaneo us activity and increased response to suprarhreshold stimuli, occurs by mu ltiple possible mechani sms. These Include activatio n ofl nunu ne pat hways, recruitment of silent ncc tceprors and expression of new recep lOrs and ion channels, The increased expression of transient receptor potent ial vanilloid I receptors (T RPV I R) Oil primary afferent s is an important mechanis m ofNeP. A recent advance co mes in the form ofa single high co ncentration (8%) capsaicin (agonist ar T RPVl Rs) patch that pro duces long-rerm an algcsic effects with ROW s}"S temic side effcces in patients. The mechanism of action relics on decreasing rhe denstry of epidermal sensory fibres from the injured area and hence loss of receptors" . lnreresdn gly a recenr hum an generic stud}" found rhar TRP chan nel polymo rphisms contribured to the somatosensory abn ormalities experienced by NeP panenrs. Thi s may have rrearmen r implications if genetic variation has a bearing on respo nse, no nrespo nse or sym pto m-specific effiC<l<' l" and would suggest subgrouping of patie nts for clinical trials" .
Another impo rtant molecu lar cha nge rhar causes periphe ral sensitization and hence drives NeP and one thai has also been validated from human generic profiling studies is rhe rerrah ydrobiopr erin (BH4) synt hesis and rucrabolism pathway, Peripheral nerve inj ury causes a marked increase in BH4levc1s in sensory neu rons linked 10 an increase in pain hyp ersensirivity".
Crmml mechanisms
Voltage gated calcium chan nels (Cav) arc irnpo rtanr for pr imary afferent neurot ransmitter release and neuron al excirabiliry, Pregabali n and gabapemt n, agents thai inhibit Cav are co nsidered by man y as "gold -standard" analgesics for NeP rreau ncm in patie nts", These drugs un iquely reverse co nditio ns of neura l sensitization such as afrer nerve injury witho ut affecting normal physiological pai n". Th is state-depende nt effect may contri but e to their favou rable side-effect profile. Their analgesic mechanism, however, remains un clear. An (26); and an enhanced role fur descending facilitation medi ated by 5-HT acnn g at pro noclceprfve spinal 5-HT2 and 3 receptor s, coupled with a decr ease in noradrenergtc descending inhibition was shown in nerve-injured rats (27, 28) . D escendin g cont rols do not just modulate pain bur are pe rm issive for th e actio ns of tricyclic antidep ressants (TCAs) and seroto nin noa rde rahn e reuprak e inhibitors (SN Rls), which rely on altering activity at monoamine synapses and are th erefore depend ent on acriviry in descending circ uits . Fu rthe r, evidence exists linkin g gabapem in's analgesic efficacy to activity within descending faclltnnory pathways (29, 30) , thus ind ivid ual variations in pain comor btdnres may un derlie th e N NT {the n umber of patient s needed ro he treated before o ne patient achieves 50% pain relief) fo r these d rugs, and so clinical investigatio ns relating the analgesic efficacy ofTCAs , SNRIs, and gabapenrlno lds with affecti ve measures co uld predict tr eatmen t responsiveness in patient s.
Neurotro phicjiWIJrl mid rt'VI'r,ingp,uhology
C urrem NeP th erapy is limit ed to sym pto m management with ou t necessarily reversing th e pathological adaptat io ns that m ainta in NeP.
Modulating the activity of ne urot rophic factor s could alter neu ronal pathophysiology and produce a disease-modifyin g effcct since th ese Bearin g in m ind thes e pe ripheral and central change'S, opportunities fur Nc r trea tmen t include red ucing neuronal hyperexcitability, increasing inh ibitio ns, neur oimrnune mod ulati on and restor ation of the neuro nal phe notype. Recent guidelines suPPOrt using hyperexcitability blockers such as gabapendn and pregabalin, which act ro modulate Cev activity, and agents thar increase descending mo noaminergic inhibitio n such as TCAs and SN RIs as first line medication for Ner. Orher licen sed excita bility blockers includ e rbc lidocaine patch and carbameae pine. Tra rnado l (a sing le molecule with bo th mu op ioid and SN RI activity) and opioids alon e, restore normal neuronal excira biliry by activating inhibitory mechani sms, ate second line treatm ents. The high co ncenrra rfon (8%) capsaicin pat ch has had success in recent clinical trials (32) . Increasing neuro nal inhibitions via acrivarion of cann abinoid recepto rs holds th erapeu tic promis e, and rhey are cur rently pro posed for refractory cases (33) .
M ultiple path ological mechanisms at mu ltiple sensory sites may unde rlie Ncr, forming the basis for com bination therapy. Accordingly gabapen rin co mbined with T CA o r o pioids appears useful fo r patient s who show partial respons e 10 rhes e drugs alo ne (33) . This avenu e is being exploite d thro ugh th e development of single molecules that com bine d ifferent mechani sms of anal gesic action . Fo r instance a novel slow-in activa tion-specific ion channel modu lato r that stabilizes voltage gated sod ium and calcium chan nels, an d attenuates NeP in a rat model of periph eral nerve injury, was recen tly described (34) . Tape nradol, which stim ulates rnu-opioid recepto rs (M a R) and acts as a norad ren aline reuprake inhibitor (N RI), app ears to be an advance o n its predecessor tramadc l (a licensed d rug with weak o pioid activity and inhibits NA and 5-HT reaprake inhibitor}, du e to removal of th e 5HT reuprake co mpone nt, so that any pronociceprlve effects of augmented 5 H T after neu ropathy arc lost (3 5, 36). 
